Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer-Reference-Cited by-同舟云学术

Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer

Published:2021-09 Issue:9 Volume:16 Page:1490-1500
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hwang David M.,Albaqer Tahani,Santiago Rex C.,Weiss Jessica,Tanguay Jeffrey,Cabanero Michael,Leung Yuki,Pal Prodipto,Khan Zanobia,Lau Sally C.M.,Sacher Adrian,Torlakovic Emina,Cheung Carol,Tsao Ming-Sound

Funder

Canadian Institutes of Health Research

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference43 articles.

1. PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee;Lantuejoul;J Thorac Oncol,2020

2. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer;Wang;Ann Oncol,2018

3. The clinicopathological and molecular associations of PD-L1 expression in non-small cell lung cancer: analysis of a series of 10,005 cases tested with the 22C3 assay;Evans;Pathol Oncol Res,2020

4. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States;Velcheti;PLoS One,2018

5. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter express study;Dietel;Lung Cancer,2019

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada;Current Oncology;2024-06-07

2. First-line Treatment Patterns and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden: A Population-based Real-world Study with Focus on Immunotherapy;Acta Oncologica;2024-04-21

3. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

4. Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma;International Immunopharmacology;2024-03

5. Plasma cell-free RNA PD-L1 or tissue PD-L1 protein expression and outcomes with first-line immunotherapy in metastatic non-small cell lung cancer;The Journal of Liquid Biopsy;2024-03